children with low dose steroid treatment, but it should be strongly taken into consideration in the clinical interpretation and should force further detailed investigation. Other drugs with a proven influence on endothelium and sympathetic activity were excluded (β-blockers, ACE inhibitors). In conclusion, the results of our study suggest that in children with nephrotic syndrome treated with CsA administered in low doses small vessel dysfunction as measured with the novel and valuable thermographic method is detected. This effect seems to be independent of sympathetic nervous system involvement, which was absent in cyclosporine A treated nephrotic children. R e f e r e n c e s 1. El-Husseini A, El-Basuony F, Mahmoud I, et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 2005; 20: 2433-8. 2. Seikaly MG, Prashner H, Nolde-Huribert B, Browne R. Long-term clinical and pathological effects of cyclosporin in children with nephrosis. Pediatr Nephrol 2000; 14: 214-7. 3. Iyengar A, Karthik S, Kumar A, Biswas S, Phadke K. Cyclosporine in steroid dependent and resistant childhood nephrotic syndrome. Indian Pediatr 2006; 43: 14-9. 4. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Muarakmi H, Yamashiro Y. Independent risk factors of chronic cyclosporine-induced nephropathy in children with nephrotic syndrome. Arch Dis Child 2006; 91: 666-70. 5. Lucini D, Milani RV, Ventura HO, Mehra MR, Messerli F, Pagani M. Study of arterial and autonomic effects of cyclosporine in humans. Hypertension 2000; 35: 1258-63. 6. Lucini D, Milani RV, Ventura HO, et al. Cyclosporine- induced hypertension: evidence for maintained baroreflex circulatory control. J Heart Lung Transplant 1997; 16: 615-20. 7. Gossmann J, Radounikli A, Bernemann A, et al. Patho- physiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? Kidney Blood Press Res 2001; 24: 111-5. 8. Elzinga LW, Rosen S, Burdmann EA, Hatton DC, Lindsley J, Bennett WM. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000; 69: 2149-53. 9. Arinsoy T, Derici U, Yuksel A, Reis KA, Sindel S. Cyclosporine-a treatment and a rare complication: Raynaud’s phenomenon. Int J Clin Pract 2005; 59: 863-4. 10. Sharma AK, Sunil S, Rustom R, et al. Cyclosporin A – related Raynaud's phenomenon in a renal transplant recipient. Transpl Int 2002; 15: 517-8. 11. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-70. 12. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Trasplant Int 2000; 13: 313-26. 13. Hausberg M, Lang D, Levers A, et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006; 24: 957-64. 14. Ring E, Ammer K, Jung A, et al. Standardization of infrared imaging. Conf Proc IEEE Eng Med Biol Soc 2004; 2: 1183-5. Cyclosporine A impairs vasodilatation without autonomic neuropathy 15. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285: 916-8. 16. Tkaczyk M, Owczarek D, Nowicki M. Tissue plasminogen activator (tPA) and its inhibitor (PAI-1) concentrations in cyclosporine A-treated children with idiopathic nephrotic syndrome. Pol Merkuriusz Lek 2003; 79: 134-6. 17. Tkaczyk M, Czupryniak A, Owczarek D, Lukamowicz J, Nowicki M. Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome. Am J Nephrol 2008; 28: 197-202. 18. Camici M. Nephrotic proteinuria and the autonomic nervous system. Saudi J Kidney Dis Transpl 2007; 18: 512-2. 19. Dibona GF, Jones SY, Sawin LL. Reflex influences on renal nerve activity characteristics in nephrosis and heart failure. J Am Soc Nephrol 1997; 8: 1232-9. 20. Czupryniak A, Kałuzyńska A, Nowicki M, Wiecek B, Bald E, Owczarek D. Raynaud's phenomenon and endothelial sysfunction in end-stage renal disease patients treated with hemodialysis. Kidney Blood Press Res 2005; 28: 27-31. 21. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 2042-8. 22. Stein CM, He H, Pincus T, Wood AJ. Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 1995; 26: 705-10. 23. Lucini D, Milani RV, Ventura HO, Mehra MR, Messerli F, Pagani M. Study of arterial and autonomic effect of cyclosporine in humans. Hypertension 2000; 35: 1258-63. 24. Gabriëls G, August C, Grisk O, et al. Impact of renal transplantation on small vessel reactivity. Transplantation 2003; 75: 689-97. 25. Lessio C, de Assunça~o Silva F, Glória MA, et al. Cyclosporine A and NAC on the inducible nitric oxide synthetase expression and nitric oxide synthesis in rat renal atrery cultured cells. Kidney Int 2005; 68: 2508-16. 26. Jourdan C, Wühl E, Litwin M, et al. Normative values for intima media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 2005; 23: 1707-15. 27. Kharalkar N, Volvano JW. Analysis of a thermal method for assessing endothelial dysfunction. Biomed Sci Instrum 2004; 40: 86-92. Arch Med Sci 4, August / 2010 577